Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Summary

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine the effects on cognition.

Interventions

• Glycine · DIETARY_SUPPLEMENT

  The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

• N-acetylcysteine · DIETARY_SUPPLEMENT

  The active arm will supplement a combination of glycine and N-acetylcysteine (GlyNAC)

• Alanine · DIETARY_SUPPLEMENT

  The placebo arm will supplement Alanine

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Age 55-85 years;
* Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20;
* Amyloid positivity on PET scan;
* Availability of a study partner.

Exclusion Criteria:

* hospitalization in past 3 months;
* use of insulin medications;
* untreated thyroid disease;
* creatinine levels \>1.5 mg/dL;
* hemoglobin concentration \<11.0 g/dL;
* known liver disease, or AST/ALT level \>2x ULN;
* history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria);
* untreated depression or other severe psychiatric disorders;
* pregnancy or nursing (unlikely in this population)

Sites (1)

• Baylor College of Medicine, Houston, Texas · RECRUITING